Elin Godager employed as Chief Business Officer

The Global Product Manager for the blood biomarker NT-proBNP at Gentian Diagnostics ASA joins the IC Targets team

IC Targets AS is very pleased to announce the appointment of Elin Godager as Chief Business Officer (CBO). Elin joins the company from the listed company Gentian Diagnostics, where she serves as Global Product Manager.  With her experience from Gentian Diagnostics and previous roles at SERO and Eurofins, she brings a unique industrial and market expertise within the diagnostics sector, with recently specialization in heart failure diagnostics. At IC Targets AS, Elin will also serve as Chief Commercial Director for CardiNor AS, the company’s recently acquired  subsidiary.

Elin is an industrial commercial leader with 20 years of experience from «hands-on» work within the In vitro Diagnostics (IVD), laboratory and biotechnology sectors. In recent years she has been specializing in business development, product management, and cross-functional team leadership. Elin has a proven expertise in managing and expanding product portfolios, developing global market strategies, and driving growth through innovative solutions. At Gentian Diagnostics she serves as Global Product Manager for the NT-proBNP immunoassay which is expected to launch this year and is designed to support the diagnosis of heart failure. She is also responsible for IVDR CE-marked Gentian Calprotectin Immunoassay (GCAL®) for the quantitative measurement of calprotectin in plasma and serum, intended as an aid in the detection and assessment of inflammation.  In her role as Global Product Manager, Elin has gained valuable insight in commercialisation of new IVD biomarkers. She has focussed on global market expansion, strategic partnerships, and on driving sustainable business outcomes.

Elin Godager comments: “I am very much looking forward to joining IC Targets and CardiNor. In my opinion, the blood test Secretoneurin (SN) and the MRI contrast agent Mangafodipir makes a unique combined tool in fighting the heart failure pandemic. I especially look forward to developing the recent acquisition, CardiNor AS, where the blood test for SN is already available in the market as a CE-marked diagnostic test. In a panel of heart failure biomarkers, SN would represent a proprietary and patented assay, which makes a unique selling point also in industrial dialogues.”

"I'm very pleased that Elin has decided to become a part of our team," welcomes Håkon Sæterøy, Executive Chairman of both IC Targets AS and CardiNor AS. “This recruitment fits very well with our plans going forward, in particular with regards to an instant refuelling of  CardiNor and an accelerated market expansion for the blood biomarker SN as a severity test for heart failure.”